Yeh Chen Lee
Overview
Explore the profile of Yeh Chen Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
271
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Friedlander M, Anderson L, Lee Y
Int J Gynecol Cancer
. 2025 Feb;
35(3):101668.
PMID: 39983368
Ovarian sex cord-stromal tumors are rare and include adult granulosa cell tumors, juvenile granulosa cell tumors, and Sertoli-Leydig cell tumors. Adult granulosa cell tumors the most prevalent malignant ovarian sex...
2.
Lee Y, Whitely A, Burling M, Anderson L, Cohen P, Naidoo M, et al.
Int J Gynecol Cancer
. 2025 Feb;
35(2):100052.
PMID: 39971437
Objective: The Rare Ovarian Tumor Module forms part of the National Gynae-Oncology Registry (NGOR) which measures compliance with the optimal care pathways for gynecologic cancer in Australia. Our objectives were...
3.
Nahm S, Kiely B, OConnell R, Lee Y, Davis A, Avall-Lundqvist E, et al.
Int J Gynecol Cancer
. 2025 Jan;
35(1):100030.
PMID: 39878283
Objective: We evaluated the accuracy of oncologists' estimates of expected survival time in recurrent ovarian cancer. Methods: Oncologists estimated expected survival time at baseline for each patient, who were then...
4.
Giani C, Salawu A, Ljevar S, Denu R, Napolitano A, Palmerini E, et al.
Am J Surg Pathol
. 2024 Oct;
49(1):27-34.
PMID: 39466087
The aim of the study was to report the outcome of primary localized low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid LGFMS/SEF (H-LGFMS/SEF). Patients with primary localized LGFMS,...
5.
Haggstrom L, Lee Y, Scott C, Harter P, Woelber L, Ledermann J, et al.
Int J Gynecol Cancer
. 2024 Oct;
34(12):1932-1939.
PMID: 39438068
Objective: There are no data, and thus no consensus, on the optimal duration of poly(ADP-ribose) polymerase (PARP) inhibitor maintenance therapy for exceptional responders (here defined as progression-free for 5 years...
6.
Grisham R, Monk B, Van Nieuwenhuysen E, Moore K, Fabbro M, OMalley D, et al.
Int J Gynecol Cancer
. 2024 Oct;
PMID: 39375168
Background: There are no approved treatments specifically for low grade serous ovarian cancer; current standard of care treatment options are limited in efficacy and tolerability. The combination of avutometinib with...
7.
Werner B, Powell E, Duggan J, Cortesi M, Lee Y, Arora V, et al.
Mol Oncol
. 2024 Aug;
18(11):2668-2683.
PMID: 39115191
The emergence of targeted therapies has transformed ovarian cancer treatment. However, biomarker profiling for precision medicine is limited by access to quality, tumour-enriched tissue samples. The use of cell-free DNA...
8.
Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, et al.
Lancet Oncol
. 2024 Aug;
25(9):1135-1146.
PMID: 39102832
Background: At the time of AtTEnd trial design, standard treatment for advanced or recurrent endometrial cancer included carboplatin and paclitaxel chemotherapy. This trial assessed whether combining atezolizumab with chemotherapy might...
9.
Lefkovits Y, Heriot N, Sporik A, Perera S, Friedlander M, Dixon C, et al.
BMC Health Serv Res
. 2024 Jul;
24(1):778.
PMID: 38978033
As medical treatment increasingly focuses on improving health-related quality of life, patient-reported outcome measures (PROMs) are an essential component of clinical research. The National Gynae-Oncology Registry (NGOR) is an Australian...
10.
Symons R, Heath F, Duggan J, Bui K, Byun L, Friedlander M, et al.
Support Care Cancer
. 2024 Apr;
32(5):292.
PMID: 38632132
Purpose: Markman's desensitisation protocol allows successful retreatment of patients who have had significant paclitaxel hypersensitivity reactions. We aimed to reduce the risk and severity of paclitaxel hypersensitivity reactions by introducing...